secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001104659-25-000811
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents reports preliminary Q4 product revenue $9.0M-$9.2M, 22-25% YoY growth; full-year ~$35.5M, 14% growth
--------------------------------------------------------------------------------

- Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.
- Full-year 2024 product revenue est $35.4M-$35.6M, ~14% growth vs $31.1M in FY 2023.
- Q4 gross margin est ~70%, up from 61% in Q3 2024, driven by resolution of manufacturing issues.
- Rights offering commenced Dec 23, 2024; subscription period ends Jan 10, 2025.
- FDA and Health Canada reviews for DrugSorb-ATR marketing application underway; decisions expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/0001104659-25-000811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/tm251882d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-000811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer